Pharma Focus Europe

Alamar Biosciences and ALZpath, Inc. Announce Strategic Collaboration for pTau217 Antibody to Further Alzheimer's Disease Research

Friday, March 01, 2024

Alamar Biosciences, a company specializing in precision proteomics for early disease detection, is excited to announce a strategic collaboration with ALZpath, a prominent developer of diagnostic solutions for Alzheimer's disease and related dementias. This partnership marks a significant milestone in advancing innovative tools for neurodegenerative disease research.

Central to this collaboration is the ALZpath pTau217 (phosphorylated tau at position 217) antibody, which plays a crucial role in investigating Alzheimer's disease and other neurodegenerative disorders. The ALZpath pTau217 antibody offers researchers a highly sensitive and specific tool for detecting and analyzing pathological changes associated with Alzheimer's disease.

Under the terms of the agreement, Alamar Biosciences will integrate ALZpath's pTau217 antibody into its NULISAqpcr™ pTau-217 Assay and its multiplexed NULISAseq™ CNS Disease Panel 120. This underscores Alamar's commitment to providing cutting-edge solutions to the neuroscience community. By combining Alamar's highly sensitive, automated NULISA™ platform with ALZpath's extensive expertise in Alzheimer's disease diagnostics, the collaboration aims to accelerate progress in neurodegenerative disease research and treatment.

"We are excited to collaborate with ALZpath to offer this ultra-sensitive pTau217 assay," said Dr. Yuling Luo, Founder, Chairman & CEO of Alamar Biosciences. "Incorporating the ALZpath antibody into the NULISA platform provides researchers with an automated solution for both single-plex and multiplexed analysis in CNS disease research."

Recently, ALZpath reported results from an international study published in JAMA Neurology involving 786 patients, showcasing the high diagnostic accuracy of its ALZpath pTau217 assay. The ultra-sensitive immunoassay demonstrated remarkable precision in identifying elevated amyloid in the brain across all cohorts, surpassing other plasma biomarker combinations and matching cerebrospinal fluid biomarkers in accuracy.

Venkat Shastri, PhD, CEO, and Co-Founder of ALZpath, echoed these sentiments, stating, "Our partnership with Alamar Biosciences perfectly aligns with our mission to drive breakthroughs in neurodegenerative research. By merging our expertise in developing cutting-edge antibodies with Alamar's high sensitivity assay and automated solutions, we aim to empower researchers worldwide in unraveling the mechanisms underlying Alzheimer's disease and related dementias."

 

Source: prnewswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva